

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/511,758 Confirmation No. 4935
 Applicant(s) : Andreas Bergmann et al.
 Filed : October 19, 2004
 Tech Cntr/AU : (unassigned)
 Examiner : (unassigned)
 Entitled : Methods for the Diagnosis of Inflammatory Diseases and Infections by Determining LASP-1 Immunoreactivity
 Attorney Reference : 121778-04341904
 Customer Number : 43569

MAIL STOP PCT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Pursuant to 37 CFR §1.97 and 1.56, the attention of the U.S. Patent and Trademark Office is hereby directed to the following disclosures made herein, which include:

REFERENCES AND RELEVANCY

- ☒ Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached, where required, as are any readily available full or partial English translations of any non-English language documents.
- ☐ Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. The references cited herein were cited for consideration in the parent application, and, pursuant to 37 CFR 1.98(d), copies of the cited references can be found in the file of the parent application (*U.S. Serial No.* , *filed*).
- ☒ Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. The references cited herein were cited in the International Search Report issued for the corresponding International application, and copies of the International Search Report and the cited references are attached for the Examiner's consideration.
- ☐ Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. The references cited herein were cited in a communication from a foreign or international patent office in a counterpart foreign or international application(s), and copies of both the relevant communication and the cited references, where required, are attached for the Examiner's consideration.

CERTIFICATION

The undersigned certifies that, pursuant to 37 CFR §1.97(e)(1),

- ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application not more than three months prior to the filing of this Statement.

RELATED CASES

- ☐ Identified in the attached Appendix are related applications directed to related technical subject matter. Copies of the related applications, where required, are attached for the Examiner's consideration. *The identification of the related U.S. patent applications is not to be construed as a waiver of secrecy for those applications, now or upon issuance of the present application as a patent.*

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- ☒ within three months of the filing date of the application and/or before the mailing date of a first Official Action on the merits, and no fee is required [37 C.F.R. §1.97(b)].
- ☐ with the appropriate certification, and no fee is required [37 C.F.R. §1.97(e)(1)].
- ☐ after the mailing date of the first Official Action on the merits, but prior to the issuance of a Final Official Action or a Notice of Allowance, and the requisite fee, if necessary, is authorized herein for payment [37 C.F.R. §1.97(c)].
- ☐ after the mailing date of the Final Official Action or Notice of Allowance, but prior to the payment of the issue fee, the requisite certification under 37 CFR §1.97(e)(1) is made herein, and the requisite fee, if necessary, is authorized herein for payment [37 C.F.R. §1.97(d)].
- ☐ with a Request for Continued Examination (RCE), and no fee is required [37 C.F.R. §1.97(b)(4)].

FEE AUTHORIZATION

- ☒ Authorization is hereby given to charge any deficient fee(s) under 37 CFR §1.16 and §1.17 as necessary to ensure the consideration of this disclosure, or to credit any fee overpayments, to Deposit Account No. 503-121.
- ☐ Authorization is hereby given to charge the requisite fee of \$180 (Fee Code 1806) for submission of this Information Disclosure Statement to Deposit Account No. 503-121.

It is respectfully requested that this information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The Examiner is further respectfully requested to return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column.

The examination and allowance of this Application is respectfully requested.

Respectfully Submitted,

MAYER BROWN ROWE & MAW LLP

By: 

Christopher M. Beck
Registration No. 52,603

Paul L. Sharer
Registration No. 36,004

Intellectual Property Group
1909 K Street, N.W.
Washington, D.C. 20006
(202) 263-3000 Telephone
(202) 263-3300 Facsimile

Date: May 25, 2005
Attachment(s): PTO Form 1449
International Search Report
Cited References

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Reference: 121778-04341904

Applicant: Andreas Bergmann et al.

Application Serial No. 10/511,758

Filing Date: October 19, 2004

Date: May 25, 2005

Page 1 of 3

Examiner: (unassigned) Group Art Unit: (unassigned)

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 4,822,733	04/1989	Morrison			
	BR 5,512,493	04/1996	Mathis et al.			
	CR 5,639,617	06/1997	Bohuon			
	DR 5,981,218	11/1999	Rio et al.			
	ER 6,756,483	06/2004	Bergmann			
	FR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country			Translation Readily Available		English Abstract	
						Enclosed	No	Enclosed	No
	GR 199 15 485 A1	10/2000	Germany			X		X	
	HR 42 27 454 C1	03/1994	Germany	* see US equivalent above			X		X
	IR 198 47 690 A1	04/2000	Germany	* see US equivalent above			X		X
	JR 0 539 477 B1	08/1995	Europe						
	KR 0 656 121 B1	04/1998	Europe						
	LR WO 00/22439	04/2000	International			X		X	
	MR WO 01/25268	04/2001	International						
	NR WO 01/36975	05/2001	International						
	OR WO 01/85986	11/2001	International						
	PR WO 01/86288	11/2001	International						
	QR WO 02/00857	01/2002	International						
	RR WO 02/10771	02/2002	International						
	SR WO 92/10200	06/1992	International						
	TR WO 98/27213	06/1998	International						
	UR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

VR	Reinhart, K. et al., "Sepsis und septischer Schock," NEED PUB NAME (2001) pp. 756-760.
WR	Schreiber, V. et al., "Lasp-1, a Novel Type of Actin-Binding Protein Accumulating in Cell Membrane Extensions," <i>Molecular Medicine</i> , vol. 4 (1998) pp. 675-687.
XR	Butt, E. et al., "Actin Binding of Human LIM and SH3 Protein Is Regulated by cGMP- and cAMP-dependent Protein Kinase Phosphorylation on Serine 146*," <i>The Journal of Biological Chemistry</i> , vol. 278, no. 18 (05/02/2003) pp. 15601-15607.
YR	Beishuizen, A. et al., "Endogenous Mediators in Sepsis and Septic Shock," <i>Advances in Clinical Chemistry</i> , vol. 33 (1998) pp. 55-131.

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Reference: 121778-04341904

Applicant: Andreas Bergmann et al.

Application Serial No. 10/511,758

Filing Date: October 19, 2004

Date: May 25, 2005

Page 2 of 3

Examiner: (unassigned)

Group Art Unit: (unassigned)

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
ZR						
AAR						

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Translation Readily Available	English Abstract
			Enclosed	No
BBR				
CCR				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

DDR	Gabay, C. et al., "Acute-Phase Proteins and Other Systemic Responses to Inflammation," <i>The New England Journal of Medicine</i> , vol. 340, no. 6 (02/11/1999) pp. 448-454.
EER	Assicot, M. et al., "High serum procalcitonin concentrations in patients with sepsis and infection," <i>The Lancet</i> , vol. 341, no. 8844 (02/27/1993) pp. 515-518.
FFR	Karzai, W. et al., "Procalcitonin – A New Indicator of the Systemic Response to Severe Infections," <i>Infection</i> , vol. 25, no. 6 (11/1997) pp. 329-334.
GGR	Oczenski, W. et al., "Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period," <i>European Journal of Anaesthesiology</i> , vol. 15 (1998) pp. 202-209.
HHR	Redl, H. et al., "Procalcitonin release patterns in a baboon model of trauma and sepsis: Relationship to cytokines and neopterin," <i>Crit Care Med</i> , vol. 28, no. 11 (2000) pp. 3659-3663.
IIR	Redl, H. et al., "Non-Human Primate Models of Sepsis," <i>Sepsis</i> , vol. 2 (1998) pp. 243-253.
JJR	Panacek, E., "Anti-TNF strategies," <i>Journal für Anästhesie</i> (2001) pp. 4-5.
KKR	Calandra, T. et al., "Protection from septic shock by neutralization of macrophage migration inhibitory factor," <i>Nature Medicine</i> , vol. 6, no. 2 (2/2000) pp. 164-170.
LLR	Garber, K., "Protein C may be sepsis solution," <i>Nature Biotechnology</i> , vol. 18 (9/2000) pp. 917-918.
MMR	Chew, C. et al., "Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell," <i>The American Psychological Society</i> , vol. 275 (1998) pp. 56-67.
NNR	Tomasetto, C. et al., "Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains," <i>FEBS Letters</i> , vol. 373 (1995) pp. 245-249.
OOR	Tomasetto, C. et al., "Identification of Four Novel Human Genes Amplified and Overexpressed in Breast Carcinoma and Localized to the q11-q21.3 Region of Chromosome 17," <i>Genomics</i> , vol. 28 (1995) pp. 367-376.
PPR	Lue, L. et al., "Inflammatory Repertoire of Alzheimer's Disease and Nondemented Elderly Microglia In Vitro," <i>GLIA</i> , vol. 35 (2001) pp. 72-79.
QQR	Hüll, M. et al., "Anti-inflammatory substances – a new therapeutic option in Alzheimer's disease," <i>DDT</i> , vol. 4, no. 6 (6/1999) pp. 275-282.
RRR	Licastro, F. et al., "Increased plasma levels of interleukin-1, interleukin-6 and α -1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?," <i>Journal of Neuroimmunology</i> , vol. 103 (2002) pp. 97-102.

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Reference: 121778-04341904

Applicant: Andreas Bergmann et al.

Application Serial No. 10/511,758

Filing Date: October 19, 2004

Date: May 25, 2005

Page 3 of 3

Examiner: (unassigned)

Group Art Unit: (unassigned)

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	SSR					
	TTR					

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Translation Readily Available	English Abstract
			Enclosed	No
UUR				
VVR				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

WWR	Akiyama, H. et al., "Inflammation and Alzheimer's disease," <i>Neurobiology of Aging</i> , vol. 21 (2000) pp. 383-421.
XXR	Hüll, M. et al., "Anti-inflammatory drugs: a hope for Alzheimer's disease?," <i>Exp. Opin. Invest. Drugs</i> , vol. 9, no. 4 (2002) pp. 671-683.
YYR	Hüll, M. et al., "Inflammatory mechanisms in Alzheimer's disease," <i>Eur Arch Psychiatry Clin Neurosci</i> , vol. 246 (1996) pp. 124-128.
ZZR	Rhodin, J. et al., "Animal Model of Alzheimer-like Vascular Pathology and Inflammatory Reaction," <i>Annals New York Academy of Sciences</i> , pp. 345-352.
AAAR	Schreiber, V. et al., "Lasp-1, a Novel Type of Actin-Binding Protein Accumulating in Cell Membrane Extensions," <i>Molecular Medicine</i> , vol. 4 (1998) pp. 675-687.
BBBR	Ghillani, P. et al., "Monoclonal Antipeptide Antibodies as Tools to Dissect Closely Related Gene Products," <i>The Journal of Immunology</i> , vol. 141, no. 9 (11/01/1998) pp. 3156-3163.
CCCR	Ghillani, P. et al., "Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases," <i>Cancer Research</i> , vol. 49, no. 23 (12/01/1989) pp. 6845-6851.
DDDR	Otto, A. et al., "Identification of human myocardial proteins separated by two-dimensional electrophoresis using an effective sample preparation for mass spectrometry," <i>Electrophoresis</i> , vol. 17 (1996) pp. 1643-1650.
EEER	Neubauer, G. et al., "Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex," <i>Nature Genetics</i> , vol. 20 (9/1998) pp. 46-50.
FFFR	Lingner, J. et al., "Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase," <i>Science</i> , vol. 276 (04/25/1997) pp. 561-567.
GGGR	Mann, M. et al., "Use of mass spectrometry-derived data to annotate nucleotide and protein sequence databases," <i>TRENDS in Biochemical Sciences</i> , vol. 26, no. 1 (1/2001) pp. 54-61.
HHHR	International Search Report for PCT/EP03/03946 dated 11/10/03
IIIR	

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.